November 2026—Fixing a problem may start with identifying it, but naming is often only the starting pistol in a much longer race. The distance between recognizing the issues of iron deficiency and related anemia, and providing a diagnosis and treatment, can often stretch months to years. Improvements in the field have been more tortoise than hare. But the pace may be picking up. This fall, the American Society …
November 2026—The first broad set of recommendations for gender-diverse patient care, endorsed by the ADLM and published in July, spell out how to interpret routine testing in this population—and go far beyond. They cover not only laboratory medicine but also anatomic pathology and informatics. Gender-affirming hormone therapy affects a relatively small group of laboratory tests, and decades of research have shown the test results can be interpreted in accordance with the patient’s affirmed gender, with a few exceptions. Tiffany Thomas, PhD, coauthor of the guidance and assistant professor in the Department of Pathology and Cell Biology at Columbia University, uses a flowchart-like way to describe the logic: “Is somebody on gender-affirming hormone therapy [GAHT]? If yes, know what few lab tests are affected by that. If it’s based on the affirmed gender, then you generally go with that.”
November 2026—This conversation is part of a series of one-on-one virtual roundtables in which CAP TODAY publisher Bob McGonnagle speaks with one vendor and one laboratory expert to spotlight a company and a customer for their laboratory solutions and work. He spoke on Aug. 6 with Emmanuel Gorospe, MD, MPH, GI medical director for Castle Biosciences, and Daniel Jondle, MD, gastrointestinal pathologist and director of the Arizona Digestive Health pathology laboratory. Dr. Jondle is a paid speaker of Castle and was compensated for his participation in this roundtable session.
November 2026—I had the pleasure last month of hosting the first-ever Global Community Reception at our CAP26 annual meeting in Las Vegas. It was a gathering of pathology leaders from outside the United States as well as senior leadership members from the CAP.
Interactive Product Guides
Use our comprehensive guides to view and compare instruments and software systems feature by feature.
FEATURED GUIDE: LIS
November 2026—The laboratory can be seen as the diagnostic ecosystem for the entire enterprise. As such, the laboratory information system, or LIS, is the CNS, or central nervous system, said Liron Pantanowitz, MD, PhD, MHA, of UPMC/University of Pittsburgh. “It’s the digital backbone to everything.”
November 2026—Fixing a problem may start with identifying it, but naming is often only the starting pistol in a much longer race. The distance between recognizing the issues of iron deficiency and related anemia, and providing a diagnosis and treatment, can often stretch months to years. Improvements in the field have been more tortoise than hare. But the pace may be picking up. This fall, the American Society …
November 2026—The first broad set of recommendations for gender-diverse patient care, endorsed by the ADLM and published in July, spell out how to interpret routine testing in this population—and go far beyond. They cover not only laboratory medicine but also anatomic pathology and informatics. Gender-affirming hormone therapy affects a relatively small group of laboratory tests, and decades of research have shown the test results can be interpreted in accordance with the patient’s affirmed gender, with a few exceptions. Tiffany Thomas, PhD, coauthor of the guidance and assistant professor in the Department of Pathology and Cell Biology at Columbia University, uses a flowchart-like way to describe the logic: “Is somebody on gender-affirming hormone therapy [GAHT]? If yes, know what few lab tests are affected by that. If it’s based on the affirmed gender, then you generally go with that.”
November 2026—A 2024 outbreak of Candidozyma auris at Harborview Medical Center in Seattle made clear the efficacy of high-throughput PCR screening in containing a C. auris outbreak. At Harborview, it did so before the onset of a single clinical infection. It was one of Washington State’s first hospital outbreaks due to C. auris, occurring one year after its first detection in Washington in 2023. “I think we were the 29th state in the country to have C. auris,” says Alex Greninger, MD, PhD, MS, MPhil, head of the Division of Infectious Disease Diagnostics, Department of Laboratory Medicine and Pathology, and the Larry Corey endowed professor of laboratory medicine and pathology, University of Washington School of Medicine.
MARKETPLACE
November 2026—NeoGenomics launched the PTEN IHC CDx, an immunohistochemistry companion diagnostic test approved by the FDA for patients with prostate adenocarcinoma. The assay detects PTEN protein loss in prostate adenocarcinoma tissue using the Ventana PTEN (SP218) RxDx assay to identify patients who may be eligible for AstraZeneca’s FDA-approved targeted therapy Truqap (capivasertib).